ArticlePloS one2025
Evaluation of the cobas plasma separation card to identify HIV-infected patients in virological failure in real-life conditions in Vietnam.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Performance of plasma separation cards for HIV drug-resistance genotyping in a resource-limited setting: comparison with plasma samples.The Journal of antimicrobial chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe standard of care for HIV-infected patients on antiretroviral therapy (ART) relies on regular monitoring of HIV viral load. Access to viral load monitoring has improved in recent years, but remains scarce in some settings. Alternatives to plasma, such as dried specimens, can help bring routine viral load testing to remote settings. This study aimed to evaluate performances of the cobas® plasma separation card (PSC) to detect virological failure at the threshold of 1,000 copies/mL in real-life conditions in Vietnam.
settingPatients were enrolled in two hospitals in Hanoi (Vietnam).
methodsThis cross-sectional evaluation enrolled 250 HIV-infected adults using convenience sampling. All provided plasma and PSC samples. The sensitivity and specificity of PSC, as compared to plasma, to identify patients in virological failure were estimated. Convenience sampling was used to reach the target numbers of 150 and 100 patients with plasma viral load ≥ and <1,000 copies/mL, respectively.
resultsOverall, 250 patients were enrolled. Of the 127 (50.8%) patients with plasma viral load ≥1,000 copies/mL, the PSC viral load was also ≥1,000 copies/mL in 126 (sensitivity (95% confidence interval (CI)): 99.2% (95.7-99.9)). Of the 123 (49.2%) patients with plasma viral load <1,000 copies/mL, the PSC viral load was also <1,000 copies/mL in 108 (specificity (95% CI): 87.8% (80.7-93.0)). Overall, the concordance rate was 93.6%.
conclusionsThis field evaluation of the cobas® PSC showed its high effectiveness in identifying patients in virological failure. The specificity was 87.8%, lower than in previous reports. However, in cases of discrepancy, the PSC viral load level was never far from the 1,000 copies/mL threshold, which may be due to measurement error inherent to the technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.